MULTIPLE TARGETS: Companies are trialing a number of new therapies for ALS, from traditional small-molecule drugs to oligonucleotide therapeutics and stem-cell treatments. These therapies may target one of several processes linked to ALS, including inflammation of the cell body 1, aggregation of proteins in the cell cytoplasm 2, defects in nuclear pore complexes 3, dysregulation of mRNA processing 4, and dysregulation of microRNAs 5.